Medline (NASDAQ:MDLN) Research Coverage Started at Citigroup

Citigroup started coverage on shares of Medline (NASDAQ:MDLN) in a report released on Monday, MarketBeat.com reports. The brokerage issued a buy rating and a $48.00 target price on the stock.

MDLN has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft initiated coverage on Medline in a report on Monday. They issued a “hold” rating and a $40.00 price objective on the stock. BNP Paribas Exane began coverage on Medline in a research report on Monday. They issued a “neutral” rating and a $38.00 target price for the company. Royal Bank Of Canada assumed coverage on shares of Medline in a research report on Monday. They set an “outperform” rating and a $47.00 price target on the stock. Barclays began coverage on shares of Medline in a research note on Monday. They issued an “overweight” rating and a $50.00 price objective for the company. Finally, Piper Sandler initiated coverage on shares of Medline in a report on Monday. They issued an “overweight” rating and a $50.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Medline presently has a consensus rating of “Moderate Buy” and an average target price of $46.70.

Medline Price Performance

Shares of NASDAQ MDLN opened at $43.41 on Monday. Medline has a 52-week low of $34.89 and a 52-week high of $45.50.

Insider Transactions at Medline

In other news, Director Andrew J. Mills purchased 2,586,206 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was bought at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the purchase, the director directly owned 2,586,206 shares of the company’s stock, valued at $74,999,974. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the transaction, the insider owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. This trade represents a 55.88% decrease in their position. The disclosure for this sale is available in the SEC filing.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.